Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur Respir J. 2005 Jan;25(1):159-72.

Neutrophils, interleukin-17A and lung disease.

Author information

  • 1Cooperative Research Centre for Chronic Inflammatory Diseases, Dept of Pharmacology, The University of Melbourne, Medical Building, Level 8, W810, Grattan Street/Royal Parade, Parkville, VIC 3010, Australia. a.linden@unimelb.edu.au

Abstract

It is now established that an excessive and sustained mobilisation of neutrophils is a hallmark of several chronic inflammatory lung disorders, including severe obstructive lung disease. This article reviews evidence that the cytokine interleukin (IL)-17A is a major orchestrator of sustained neutrophilic mobilisation. Current evidence suggests that IL-17A is produced by T-lymphocytes, and that it exerts an orchestrating effect on the accumulation and associated activity of neutrophils in the bronchoalveolar space indirectly, through an induced release of specific cytokines and colony-stimulating factors in resident lung cells. Although the involvement of IL-17A in inflammatory lung disorders is supported by several recent studies, its causative role is still uncertain. However, the unique position of interleukin-17A at the interface between acquired and innate immunity puts this cytokine forward as an important signal for the reinforcement of host defence; it also implies that interleukin-17A may constitute a useful target for pharmacotherapeutic intervention.

PMID:
15640338
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk